Zacks Investment Management’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-11,432
Closed -$141K 737
2025
Q4
$141K Buy
+11,432
New +$122K ﹤0.01% 690
2019
Q1
Sell
-20,113
Closed -$1.19M 548
2018
Q4
$1.19M Sell
20,113
-871
-4% -$56.1K 0.03% 317
2018
Q3
$1.38M Buy
20,984
+134
+0.6% +$7.82K 0.03% 343
2018
Q2
$1.05M Buy
20,850
+417
+2% +$21.7K 0.02% 416
2018
Q1
$1.08M Buy
20,433
+1,488
+8% +$74.2K 0.02% 395
2017
Q4
$880K Buy
+18,945
New +$797K 0.02% 428
2016
Q3
Sell
-60,441
Closed -$1.7M 669
2016
Q2
$1.7M Sell
60,441
-43,200
-42% -$1.69M 0.05% 236
2016
Q1
$3.77M Buy
103,641
+655
+0.6% +$23.1K 0.12% 148
2015
Q4
$4.12M Buy
102,986
+3,470
+3% +$121K 0.13% 144
2015
Q3
$2.83M Buy
99,516
+44,861
+82% +$1.48M 0.1% 162
2015
Q2
$1.8M Buy
54,655
+192
+0.4% +$5.95K 0.06% 194
2015
Q1
$1.57M Buy
54,463
+485
+0.9% +$13.9K 0.05% 209
2014
Q4
$1.47M Sell
53,978
-1,946
-3% -$46.4K 0.05% 207
2014
Q3
$1.19M Sell
55,924
-5,355
-9% -$123K 0.04% 221
2014
Q2
$1.38M Sell
61,279
-18,467
-23% -$430K 0.05% 205
2014
Q1
$2.02M Buy
+79,746
New +$2.01M 0.07% 176

Other funds holding EBS

Zacks Investment Management's EBS Position: Q1 2026 in Review

Zacks Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 11,432 shares — an estimated $141K sold.

Zacks Investment Management first reported a position in EBS in Q1 2014 and held it in 16 quarters. The position peaked at $4.12M in Q4 2015. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • Zacks Investment Management reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
  • Zacks Investment Management sold 11,432 Emergent Biosolutions shares in Q1 2026, an estimated $141K.
  • Zacks Investment Management first reported a position in Emergent Biosolutions in Q1 2014 and held it in 16 quarters.
  • Zacks Investment Management's Emergent Biosolutions position peaked at $4.12M in Q4 2015.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.